Skip to main content
THERACRYF PLC logo

THERACRYF PLC — Investor Relations & Filings

Ticker · TCF ISIN · GB00BSVYN304 LEI · 213800NO3E6TSTQO8K20 IL Professional, scientific and technical activities
Open in API
Filings indexed 361 across all filing types
Latest filing 2025-03-11 Major Shareholding Noti…
Country GB United Kingdom
Listing IL TCF

About THERACRYF PLC

https://theracryf.com/

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified as an 'RNS Number : 2012A' filing from 'Theracryf PLC' dated '11 March 2025'. The content is structured as a 'TR-1: Standard form for notification of major holdings', detailing changes in voting rights held by an individual ('James Robert Kight'). This type of mandatory disclosure regarding significant changes in share ownership thresholds falls under regulatory reporting concerning major shareholders. While it is a regulatory filing, the specific nature of reporting changes in major shareholdings aligns most closely with the definition for Major Shareholding Notification (MRQ). It is not an Earnings Release (ER), Annual Report (10-K), or a general announcement (RNS), but a specific disclosure about ownership thresholds.
2025-03-11 English
Result of General Meeting
AGM Information Classification · 99% confidence The document is identified by the 'RNS Number' header and contains an announcement titled 'Result of General Meeting and Total Voting Rights'. It explicitly states that 'at the General Meeting held today... all resolutions were duly passed'. This directly relates to the outcome of a shareholder vote. The most specific category for official results from shareholder votes is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it mentions the General Meeting (AGM), the core content is the result declaration, not the AGM presentation itself (AGM-R) or the proxy solicitation materials (PSI). Since it is a formal regulatory announcement distributed via RNS, DVA is the best fit.
2025-03-07 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a formal notification filed via RNS (Regulatory News Service) detailing a transaction by a Person Discharging Managerial Responsibilities (PDMR). Specifically, it reports that Dr. Helen Kuhlman, the Chief Business Officer, purchased Ordinary Shares of TheraCryf plc. This type of insider transaction report, detailing personal share dealings by directors/executives, directly corresponds to the definition of 'Director's Dealing' (DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2025-03-04 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is filed under 'RNS Number : 2557Y'. This form is used to report changes in major shareholdings, which directly relates to changes in voting rights thresholds. This specific type of regulatory disclosure, reporting insider or major shareholder transactions/holdings, aligns best with the 'Major Shareholding Notification' category (MRQ). Although it is an RNS filing, MRQ is more specific than the general RNS fallback.
2025-02-24 English
£4.25m Placing and Subscription, Notice of GM
Share Issue/Capital Change Classification · 99% confidence The document announces a Placing and Subscription to raise £4.25 million, details the use of proceeds, appoints a joint broker (Turner Pope), and provides a Notice of General Meeting required to approve the conditional element of the fundraising. The text explicitly mentions that a Circular containing further details and the notice of the General Meeting is expected to be published and despatched to Shareholders on or around today's date, and that an extract is set out in Appendix I. The document itself is a formal announcement detailing a significant corporate action (fundraising) that requires shareholder approval via a General Meeting, which is typically preceded or accompanied by a Proxy Statement or Circular. Since it details the fundraising, the associated shareholder meeting notice, and the appointment of directors/brokers, it strongly aligns with a document related to shareholder voting and corporate governance surrounding a major event. However, the core event is the capital raise and the required shareholder vote. The presence of the 'Notice of General Meeting' and the conditions tied to shareholder approval points towards materials related to soliciting shareholder votes or announcing the meeting itself. Given the options, this announcement details the capital raise and the necessary shareholder meeting to approve it. This structure is common in announcements that precede or are part of the materials for a General Meeting. Since it contains the notice for the General Meeting and details the resolutions needed, it is closely related to shareholder voting materials. The most fitting category for an announcement detailing a capital raise contingent on shareholder approval and including the notice of the meeting is 'Capital/Financing Update' (CAP) or potentially related to the meeting itself. However, the document is a comprehensive regulatory announcement (RNS Number: 7150X) detailing the financing, which is the primary driver. Since it is a full announcement detailing the financing terms and the required shareholder vote, 'CAP' (Capital/Financing Update) is highly appropriate. It is not just a 'Report Publication Announcement' (RPA) because it contains substantive, time-sensitive financial and corporate action details, not just a pointer to another document. It is too specific for the general 'RNS' fallback. The key elements are the £4.25m fundraising and the associated General Meeting notice.
2025-02-19 English
Appointment of Dr Alastair Smith as Chair
Board/Management Information Classification · 98% confidence The document is identified by the RNS Number header and contains a formal announcement dated February 19, 2025, regarding the appointment of a new Non-executive Chair, Dr Alastair Smith. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the specific content dictates the MANG classification over the general RNS fallback.
2025-02-19 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.